Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

An analysis of succinate dehydrogenase B in pleural mesothelioma.

Discover oncology·2026
Same author

Enhancing triapine treatment: strategies for dose optimization and methemoglobin level mitigation.

Cancer chemotherapy and pharmacology·2026
Same author

TLR7 alters the maternal immune landscape during influenza A infection to increase maternal and fetal morbidity.

Science advances·2026
Same author

Genotypic and phenotypic spectrum of hereditary spastic paraplegia 56: insights from novel CYP2U1 variants and a literature review.

BMC neurology·2026
Same author

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Nature communications·2026
Same journal

Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Corrigendum to "European experience on oncological outcomes of patients with early stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" [Lung Cancer J. 217 (2026) 109410].

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Proportion of lung cancer patients eligible for screening in France: Data from the KBP-2020-CPHG study.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Prognostic impact of the 9th vs 8th TNM classification in small-cell lung cancer. a population-based study.

Lung cancer (Amsterdam, Netherlands)·2026
Same journal

Corrigendum to "European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy" Published in [Lung Cancer https://doi.org/10.1016/j.lungcan.2026.109410].

Lung cancer (Amsterdam, Netherlands)·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

14.0K

Molecular testing in oncology: problems, pitfalls and progress.

Cathal P O'Brien1, Sarah E Taylor2, John J O'Leary3

  • 1Cancer Molecular Diagnostics, St. James's Hospital, Dublin 8, Ireland; Department of Histopathology, St. James's Hospital, Dublin 8, Ireland; Department of Histopathology, Trinity College Dublin, Dublin 8, Ireland.

Lung Cancer (Amsterdam, Netherlands)
|January 30, 2014
PubMed
Summary
This summary is machine-generated.

Molecular diagnostics in oncology and pathology are advancing rapidly, driven by technologies like Next Generation Sequencing (NGS). Careful biomarker selection and assay design are crucial to overcome implementation challenges and ensure accurate cancer diagnostics.

Keywords:
AlkBiomarkerEGFRLung cancerMolecular diagnosticsNGS

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Experiment Videos

Last Updated: May 3, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

14.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Area of Science:

  • Oncology
  • Pathology
  • Molecular Diagnostics
  • Biomarker Discovery

Background:

  • Advances in understanding cancer's molecular basis have propelled oncology and pathology.
  • Next Generation Sequencing (NGS) and multiplex assays enable widespread clinical molecular diagnostics.

Purpose of the Study:

  • To highlight the promise and challenges of implementing molecular diagnostics in clinical settings.
  • To emphasize the importance of careful biomarker selection and assay design for accurate cancer testing.

Main Methods:

  • Review of technological advancements, including Next Generation Sequencing (NGS).
  • Discussion of biomarker types: predictive, prognostic, standard of care, and surrogate.
  • Consideration of technical challenges: sample heterogeneity, population differences, and assay design.

Main Results:

  • Molecular diagnostics offer significant promise but face implementation hurdles.
  • Choosing appropriate biomarkers and understanding their relationships is critical.
  • Technical and ethical considerations are paramount for adopting new technologies like NGS.

Conclusions:

  • Successful clinical integration of molecular diagnostics requires strategic planning.
  • Careful management of biomarkers, assay design, and technological implementation is essential for advancing cancer care.
  • Regulatory landscapes, such as FDA regulations for companion diagnostics, influence assay selection.